Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Atara Biotherapeutics ( (ATRA) ) has shared an update.
On July 14, 2025, Atara Biotherapeutics announced the resubmission of its Biologics License Application (BLA) for tabelecleucel (tab-cel®) to the U.S. FDA, aimed at treating Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD). This resubmission follows collaborative efforts with Pierre Fabre Laboratories to address manufacturing observations noted in a previous Complete Response Letter. Approval of the BLA could trigger a $40 million milestone payment from Pierre Fabre Laboratories. Atara is also finalizing the transfer of clinical studies and operational activities related to tab-cel to Pierre Fabre Laboratories, while maintaining sponsorship of the BLA. The company projects that its current financial resources will support operations into the first quarter of 2026, contingent on achieving BLA approval.
The most recent analyst rating on (ATRA) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Atara Biotherapeutics stock, see the ATRA Stock Forecast page.
Spark’s Take on ATRA Stock
According to Spark, TipRanks’ AI Analyst, ATRA is a Neutral.
Atara Biotherapeutics’ overall stock score reflects significant financial distress and valuation challenges, partially offset by favorable technical indicators and regulatory progress. The company’s financial instability and negative earnings outlook are the most significant risks, while recent FDA clearance provides a positive development.
To see Spark’s full report on ATRA stock, click here.
More about Atara Biotherapeutics
Atara Biotherapeutics, Inc., headquartered in Southern California, is a leader in T-cell immunotherapy, focusing on developing transformative therapies for cancer and autoimmune diseases using its novel allogeneic Epstein-Barr virus (EBV) T-cell platform. The company is recognized for its advanced T-cell platform that does not require T-cell receptor or HLA gene editing, and it is the first to receive regulatory approval for an allogeneic T-cell immunotherapy.
Average Trading Volume: 53,776
Technical Sentiment Signal: Sell
Current Market Cap: $62.72M
Find detailed analytics on ATRA stock on TipRanks’ Stock Analysis page.